Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

TJAB Forms Drug Development JV with Antisense of Australia

publication date: Jul 19, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) has formed a JV with Antisense Therapeutics of Australia to develop a drug discovered by ANP. The drug, ATL1102, is aimed at multiple sclerosis, stem cell mobilization and asthma. TJAB will be responsible for marketing in China and Hong Kong, while ANP will retain those duties for the rest of the world. More details....

Stock Symbol: (ASX: ANP)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors